8th Complement-Based Drug Development Summit

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?

With assets in nephrology, ophthalmology, neurodegeneration, and inflammation all progressing through to the clinic, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies.

Join 100+ industry leaders, scientists, and clinicians at the premier, end-to-end, 8th Complement-Based Drug Development Summit to shape the future of complementtargeted therapies. Across 3 days of content, you can expect discussions spanning:

• Strategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets
• Navigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication
• Exploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort
• Moving from targeting rare disease with complement inhibitors to larger patient populations
• Navigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster

Key benefits of attending:

• Delve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with Apterion Therapeutics, Annexon Bio,and Sanofi to determine the most effective pathway when developing complement inhibitors
• Explore the potential for combination therapies with existing complement therapies and other modalities with CSL Behring for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.
• Discuss the move from targeting rare diseases with complement inhibitors to more common diseases with IgM Biosciences, Grid Therapeutics,and Astellas, to target larger patient populations
• Evaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with Beacon Therapeutics and Arrowhead Pharmaceuticals
• 8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval